1. Introduction {#sec1-sensors-17-02018}
===============

Immunoassays are biochemical tests used to detect or quantify a specific substance, such as analytes in samples of blood or bodily fluid, using immunological reactions. Immunoassay methods include the enzyme-linked immunosorbent assay (ELISA) \[[@B1-sensors-17-02018]\], radioimmunoassay (RIA) \[[@B2-sensors-17-02018]\], real-time polymerase chain reaction (real-time PCR) \[[@B3-sensors-17-02018]\], immunonephelometry \[[@B4-sensors-17-02018]\], etc. Some immunoassays, such as ELISA, require two antigens and separation of the unbound antigens, which can be tedious and time-consuming. On the other hand, magnetic immunoassay (MIA) is a novel type of diagnostic technology using magnetic nanoparticles (MNPs) as labels to replace conventional ELISA, RIA, real-time PCR, etc. MNPs are coated with dextran so that they are encapsulated or glued together with polymers in sizes of nanometers or even micrometers. In immunomagnetic tests, MNPs are first biofunctionalized against antibodies to target antigens. Reagents consisting of biofunctionalized magnetic nanoparticles (BMNPs) are then mixed with samples. Due to the molecular interactions among BMNPs and biomarkers, magnetic clusters are conjugated in the reaction process and their magnetic properties change after the association. The magnetic signal due to the changes of magnetic properties is analyzed in order to determine the unknown amount of biomarkers. Magnetic properties (magnetic relaxation \[[@B5-sensors-17-02018],[@B6-sensors-17-02018]\], remanent magnetization \[[@B7-sensors-17-02018]\], Brownian relaxation \[[@B8-sensors-17-02018]\], saturation magnetization \[[@B9-sensors-17-02018]\], spin-spin relaxation of NMR \[[@B10-sensors-17-02018]\], and alternative-current (AC) susceptibility reduction \[[@B11-sensors-17-02018],[@B12-sensors-17-02018],[@B13-sensors-17-02018],[@B14-sensors-17-02018],[@B15-sensors-17-02018]\], etc.) have been developed recently. Magnetic immunoassays can be carried out simply by mixing reagents and tested samples together and taking physical measurements. Additionally, the background noise of magnetic detection is negligible; hence, high detection sensitivity can be achieved.

Based on the increment of saturation magnetization, ΔM~S~, Chieh et al. \[[@B16-sensors-17-02018]\] recently reported another assay method that used a vibrating sample magnetometer (VSM) to label tumor biomarkers of alpha-fetoprotein (AFP) in clinical studies via the ΔM~S~/M~S~-versus-Ф~AFP~ curve at the saturation field H~S~, where Ф~AFP~ was the concentration of AFP. The authors demonstrated that VSM can be used to screen patients carrying hepatocellular carcinoma (HCC) with sensitivity better than the criterion set in clinics (0.02 μg/mL). It would be interesting to see whether we can screen HCC patients with high detection sensitivity at low magnetic fields (H). Therefore, in this work, we propose a detection method based on the scaling characteristic of the normalized increment of magnetization at low magnetic fields. It is found that M~AFP~ and τ~eff~ are enhanced when Ф~AFP~ increases, where M~AFP~ is the magnetization of the reagent and τ~eff~ is the effective relaxation time. We attribute those results to the molecular interactions among BMNPs in the associated magnetic clusters, which contribute extra magnetization and in turn enhance τ~eff~. The scaling characteristic of (ΔM~AFP~/M~AFP,0~)-versus-Φ~AFP~ curves at low magnetic fields is demonstrated, and the screening of HCC patients via the scaling characteristic is verified in clinical studies.

2. Experiments {#sec2-sensors-17-02018}
==============

The MNPs in this study were dextran-coated Fe~3~O~4~ (MF-DEX-0060, MagQu Co., Ltd., New Taipei City, Taiwan) with a mean core diameter of \~35 nm, as detected by x-ray diffraction (D-500, Siemens). The BMNPs were Fe~3~O~4~-anti-AFP (MF-AFP-0060, MagQu Co. Ltd., New Taipei City, Taiwan), and the biotarget was AFP, which is a biomarker for diagnosing HCC. When the AFP level is abnormally high before surgery or other therapy, it is expected to fall to normal levels following the successful removal of all cancer cells.

In performing the AFP tests, the BMNPs consisting of Fe~3~O~4~-anti-AFP were first mixed with AFP. The changes of magnetic properties after the reaction process were then characterized using a VSM (Model Hystermag, MagQu Co., Taiwan) and AC susceptometer. The data of the normalized increments of magnetization ΔM/M were analyzed for a magnetic immunoassay. The AC susceptibility was measured by a highly balanced AC susceptometer in order to monitor the real-time reaction process. The AC susceptibility χ~ac~(ω) can be expressed as follows: where i = (−1)^1/2^, χ''/χ' = tanθ = ωτ~eff~(t), and θ is the phase lag of the time-varying magnetization M(t) with respect to the applied AC magnetic field H(t).

[Figure 1](#sensors-17-02018-f001){ref-type="fig"}a shows the detection schematic of the VSM used for characterizing M after the BMNPs had conjugated with AFP. In the measurement of M, the sample vibrated with a frequency of \~30 Hz. The magnetic signal was detected with a second-order gradient coil. An electromagnet provided a magnetic field of up to 1.0 Tesla, so that the M--H curves of reagents were characterized. In assaying AFP, a reagent composed of 40 μL Fe~3~O~4~-anti-AFP was mixed with 60 μL AFP. We measured the M--H curves and analyzed the magnetization enhancement (ΔM) at low external fields (H) to establish the relationship between ΔM/M and the concentrations of AFP (Ф~AFP~). [Figure 1](#sensors-17-02018-f001){ref-type="fig"}b shows the high-T~C~ SQUID-based AC susceptometer for characterizing the AC magnetic susceptibility. The excitation frequency is \~16 kHz. The magnetic signal of BMNPs is picked up by a gradient coil that is coupled to a high-T~C~ SQUID via a flux transformer. The detailed design of the pickup coil, gradient coil, and compensation coil in a homemade AC susceptometer that did not use a high-T~c~ SQUID was reported in \[[@B17-sensors-17-02018],[@B18-sensors-17-02018]\].

The reagent was composed of anti-AFP-conjugated Fe~3~O~4~ labeled as Fe~3~O~4~-anti-AFP. The bio-target was AFP. [Figure 2](#sensors-17-02018-f002){ref-type="fig"} depicts Fe~3~O~4~-anti-AFP, AFP, and a magnetic cluster composed of Fe~3~O~4~-anti-AFP-AFP.

3. Results and Discussion {#sec3-sensors-17-02018}
=========================

This section addresses and discusses the results from the characterization of magnetic properties when biofunctionalized Fe~3~O~4~-anti-AFPs are associated with AFP. Additionally, we present the results from the real-time association of Fe~3~O~4~-anti-AFP with AFP via the time-dependency studies of τ~eff~(t) in the reaction process using the technique of AC susceptibility. We also briefly summarize the findings. Finally, we present the clinical research on screening HCC patients via normalized increments of magnetization and address and discuss advances in sensitive bio-sensing.

[Figure 3](#sensors-17-02018-f003){ref-type="fig"} shows ΔM~H~ as a function of Ф~AFP~ at μ~0~H = 0.02 T, 0.06 T, and 0.16 T and ΔM~H~ = M~H~(Ф~AFP~) − M~H~(Ф~AFP~ = 0). For a fixed magnetic field at μ~0~H = 0.02 T, ΔM~H~ = 0.015 emu/g when Ф~AFP~ = 0.01 μg/mL, and ΔM~H~ increases to ΔM~μ0H\ =\ 0.02\ T~ = 0.13 emu/g when Ф~AFP~ = 10 μg/mL. For μ~0~H = 0.16 T, ΔM~μ0H\ =\ 0.16\ T~ = 0.03 emu/g when Ф~AFP~ = 0.01 μg/mL, and ΔM~H~ increases to ΔM~μ0H\ =\ 0.16\ T~ = 0.23 emu/g when Ф~AFP~ = 10 μg/mL. Hence, we have demonstrated an enhancement of ΔM~H~ when Ф~AFP~ increases at a fixed magnetic field. We attribute those enhancements to the fact that more magnetic clusters are associated and stronger magnetic interactions among BMNPs are present.

[Figure 4](#sensors-17-02018-f004){ref-type="fig"} shows the normalized increment of magnetization, ΔM~AFP~/M~AFP,0~, as a function of Ф~AFP~ at μ~0~H = 0.02 T, 0.06 T, and 0.16 T, where ΔM~AFP~ = M(Ф~AFP~) − M(Ф~AFP~ = 0), M~AFP,0~ = M~H~(Ф~AFP~ = 0). It is found that ΔM~AFP~/M~AFP,0~ as a function of Ф~AFP~ in external magnetic fields can be scaled to a universal logistic function described by the following formula \[[@B15-sensors-17-02018]\]: where A and B are dimensionless quantities and Ф~0~ is dimensionless. The fitting parameters are as follows: A = 0.173, B = 34.2, Φ~0~ = 3410 μg/mL, and γ = 0.5. We have established a relationship between ΔM~AFP~/M~AFP,0~ and Ф~AFP~ with Ф~AFP~ varied from 0.01 μg/mL to 10 μg/mL. Therefore, the unknown amounts of AFP can be determined via a scaling characteristic of the (ΔM~AFP~/M~AFP,0~)-versus-Ф~AFP~ curve, which is versatile and can be applied to assay other biomarkers. In assaying other biomarkers, the relationship between ΔM~biomarker~/M~biomarker,0~ and Ф~biomarker~ is first established and then ΔM~biomarker~/M~biomarker,0~ and the Ф~biomarker~ curve are applied to determine the unknown amount of biomarkers quantitatively.

To observe the real-time association of τ~eff~ when Fe~3~O~4~-anti-AFPs are associated with AFP directly, we characterize the time-dependent τ~eff~ via the following formula: tanθ = ωτ~eff~, where χ''/χ' = tanθ and χ' and χ'' are the real and imaginary parts of AC susceptibility in Equation (1). [Figure 5](#sensors-17-02018-f005){ref-type="fig"}a shows τ~eff~(t) as a function of time in the reaction process. The reagent shows τ~eff~ = \~1.3 μs, and τ~eff~ is stable to τ~eff~ = 1.3 μs at t = 7200 s. It takes approximately 6000 s for the reagent to complete the association and τ~eff~ is increased to τ~eff~ = \~1.75 μs with Ф~AFP~ = 1 μg/mL. Therefore, a detection time of 7200 s is suggested. The real-time association of Fe~3~O~4~-anti-AFP with AFP is verified.

The Brownian relaxation time, τ~B~, is a function of the hydrodynamic volume of a magnetic particle, V~H~, the viscosity of the medium, η, the Boltzmann's constant, k, and the absolute temperature, T, which is expressed as follows \[[@B19-sensors-17-02018]\]:

In the reaction process, we assume that the viscosity and temperature are constant. The Brownian relaxation time is proportional to the hydrodynamic volume of the magnetic particle. The ratio of the increase in τ~eff~ after the reaction process is 1.35 with an Ф~AFP~ value of 1 μg/mL. The effective diameter of the magnetic cluster is 2.4 times larger than a single magnetic particle when Ф~AFP~ is 1 μg/mL. It presents the formation of magnetic clusters during the reaction process.

[Figure 5](#sensors-17-02018-f005){ref-type="fig"}b shows Δτ~eff~/τ~eff,0~ as a function of Ф~AFP~ with Ф~AFP~ ranging from Ф~AFP~ = 0.001 μg/mL to Ф~AFP~ = 1 μg/mL. The reagent shows τ~eff~ = 1.3 μs, and τ~eff~ is enhanced to τ~eff~ = \~1.75 μs when Ф~AFP~ = 1 μg/mL. The enhancement of τ~eff~ is due to the presence of magnetic clusters in the reaction process. The magnetic interaction among BMNPs enhances M, which in turn increases τ~eff~. The (Δτ~eff~/τ~eff,0~)-versus-Ф~AFP~ curve follows the characteristic curve \[[@B15-sensors-17-02018]\]: where Δτ~eff~ = τ~eff~(7200 s) − τ~eff~(t = 0) and τ~eff,0~ = τ~eff~(t = 0). The curve is fitted to the following parameters: A~1~ = −0.013 μs, B~1~ = 0.56 μs, Φ~0~ = 0.15 μg/mL, and γ = 0.52. Equation (4) reveals the concentration dependency of the characteristic of Δτ~eff~/τ~eff,0~ after the BMNPs have completed the association with AFP. The (Δτ~eff~/τ~eff,0~)-versus-Φ~AFP~ curve shown in [Figure 5](#sensors-17-02018-f005){ref-type="fig"}b can be applied to screening patients carrying HCC. Normalized Δτ~eff~/τ~eff,0~ is analyzed instead of Δτ~eff~ for a magnetic immunoassay, because this enables us to eliminate minor differences in magnetic signals due to minor differences in sample amounts used from run to run, which will enhance the detection sensitivity.

Detection sensitivity can be defined by the noise level with standard deviations for the detected signal at low concentrations \[[@B20-sensors-17-02018]\]. In this study, the detection sensitivity levels are 0.0024 μg/mL and 0.0177 μg/mL, as determined by measuring Δτ~eff~/τ~eff,0~ and ΔM~AFP~/M~AFP,0~ respectively. The reference criterion of the AFP serum level for HCC is 0.02 μg/mL. The sensitivity of both methods reaches the criteria for a clinical AFP assay. The feasibility of AFP is demonstrated by measuring Δτ~eff~/τ~eff,0~ and ΔM~AFP~/M~AFP,0~.

In this study, we characterized magnetic properties when BMNPs are associated with AFPs for biomedical applications. The findings in the characterization of magnetic properties are briefly summarized as follows. First, M and τ~eff~ are enhanced when reagents composed of BMNPs are conjugated with AFP in the reaction process. The magnetic interactions among BMNPs in magnetic clusters enhance M, which in turn increases τ~eff~. Second, the real-time association of BMNPs with AFP was demonstrated in the time-dependent τ~eff,~. Third, bio-detection based on the (Δτ~eff~/τ~eff,0~)-versus-Φ~biomarkers~ curve provided a sensitive methodology for assaying unknown amounts of AFP, and BMNPs could be applied to assay large molecules such as AFP as well as small molecules such as C-reactive protein(CRP) \[[@B21-sensors-17-02018]\]. Finally, the proposed detection methodology based on the (Δτ~eff~/τ~eff,0~)-versus-Φ~biomarkers~ curve was versatile, and the (ΔM~AFP~/M~AFP,0~)-versus-Ф~AFP~ curves shown in [Figure 4](#sensors-17-02018-f004){ref-type="fig"} were scaled to a characteristic function described by Equation (2). The results confirm that both changes in ΔM~AFP~/M~AFP,0~ and Δτ~eff~/τ~eff,0~ are caused by the formation of magnetic clusters and can be applied to sense a wide variety of biomarkers.

The sensitivity levels of Δτ~eff~/τ~eff,0~ and ΔM~AFP~/M~AFP,0~ reach the criteria for a clinical AFP assay. The cost of a high-T~C~ SQUID-based AC susceptometer is much higher than that of a VSM with a low-strength magnet. The low-strength VSM has high potential for commercial and clinical applications. Therefore, the screening of HCC patients can be addressed by measuring ΔM~H~/M~H,0~. Since the data shown in [Figure 4](#sensors-17-02018-f004){ref-type="fig"} are scaled to a characteristic function described by Equation (2), it would be interesting to verify whether we can also obtain high detection sensitivity at low magnetic fields via Equation (2). Hence, we can apply Equation (2) at a low magnetic field, say μ~0~H = 0.065 T, to analyze AFP levels in clinical studies. To verify this, we show in [Figure 6](#sensors-17-02018-f006){ref-type="fig"}a (ΔM~AFP~/M~AFP,0~)-versus-Ф~AFP~ with data analyzed at μ~0~H = 0.065 T, where ΔM~AFP~ = M~H~(Ф~AFP~) − M~H~(Ф~AFP~ = 0) and M~AFP,0~ = M~H~(Ф~AFP~ = 0). The background magnetic signal of serum from healthy persons in ΔM~AFP~/M~AFP,0~ is deducted in the data analysis. To screen patients carrying HCC and healthy persons, we mixed 40 μL 0.1 emu/g of reagent with 60 μL of serum. The data for establishing the standard curve are marked with a solid dot (•). AFP levels in serum for HCC patients are marked with an open triangle (**Δ**), while AFP levels for healthy persons are marked with an open square (**□**). The reference criterion of the AFP serum level for HCC is 0.02 μg/mL. We found that the average AFP levels for patients carrying HCC were higher than \~0.2 μg/mL, which is significantly higher than the criterion set in clinics (0.02 μg/mL). The average AFP levels for healthy persons were below \~0.02 μg/mL, except for one healthy person who showed a false positive (AFP level = \~0.03 μg/mL). [Figure 6](#sensors-17-02018-f006){ref-type="fig"}b shows ΔM~AFP~/M~AFP,0~ as a function of Ф~AFP~ with data analyzed at 0.16 T. HCC patients showed AFP levels higher than the clinical criterion. Healthy persons showed AFP levels of 0.001 μg/mL, except for one healthy person with a higher AFP level of \~0.4 μg/mL. The estimated values of Ф~AFP~ were different between μ~0~H = 0.065 T and 0.16 T. It was probably due to the magnetic clustering effect that induces background magnetic noises. Besides, the ΔM~AFP/~ΔM~AFP,0~ of serum tested at 0.16 T is higher than that at 0.065 T. It leads that the estimated AFP concentration at 0.16 T is higher than that at 0.065 T. The reason may be due to the larger background magnetization of serum than that of the AFP solution. The reference magnetization, M(Ф~AFP~ = 0), in the clinical test may be considered by using the averaging magnetization of healthy persons to reduce the effect in the clinical test. Thus, the feasibility of screening HCC patients by assaying AFP levels in serum was verified.

The AFP level in serum was recently determined via the ΔM~S~-versus-Ф~AFP~ curve at the saturation field μ~0~H~S~ = \~0.4 T \[[@B16-sensors-17-02018]\], where ΔM~S~ is the increment of the saturated magnetization. A clear demarcation between the normal group and the HCC group was verified in the test results, which indicates the feasibility of using ΔM~S~-versus-Ф~AFP~ at the saturation field as the primary analysis factor for identifying the AFP risk level in patients. In this work, the screening of HCC patients was fulfilled at low magnetic fields, which makes the detection platform simple for biomedical application users.

4. Conclusions {#sec4-sensors-17-02018}
==============

In summary, we performed measurements of magnetization (M--H curves) and AC susceptibility when reagents consisting of Fe~3~O~4~-anti-AFP were conjugated with AFP. The scaling characteristic of (ΔM~AFP~/M~AFP,0~)-versus-Φ~AFP~ curves at low magnetic fields was demonstrated, and bio-sensing using BMNPs via increments of magnetization was proposed. We showed that BMNPs can be applied to assay large as well as small molecules. The screening of HCC patients via the scaling characteristic was verified in clinical studies. The detection mechanism based on the scaling characteristic showed potential to develop a compact VSM with a low magnetic field for biomedical applications.
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![Detection scheme of (**a**) vibrating sample magnetometer; (**b**) high-Tc SQUID-based AC susceptometer.](sensors-17-02018-g001){#sensors-17-02018-f001}

![Pictures showing (**a**) biofunctionalized Fe~3~O~4~-anti-AFP; (**b**) AFPs; (**c**) magnetic cluster composed of Fe~3~O~4~-anti-AFP-AFP.](sensors-17-02018-g002){#sensors-17-02018-f002}

![The increments of magnetization ΔM~H~ as a function of Ф~AFP~ at low magnetic fields at μ~0~H = 0.02 T, 0.06 T, 0.16 T.](sensors-17-02018-g003){#sensors-17-02018-f003}

![The normalized increment of magnetization ΔM~AFP~/M~AFP,0~ as a function of Ф~AFP~ with data analyzed at μ~0~H = 0.02 T, 0.06 T and 0.16 T.](sensors-17-02018-g004){#sensors-17-02018-f004}

![(**a**) τ~eff~ as a function of time, (**b**) Δτ~eff~/τ~eff,0~ as a function of Ф~AFP~ with Ф~AFP~ from Ф~AFP~ = 0.001 μg/mL to Ф~AFP~ = 1 μg/mL.](sensors-17-02018-g005){#sensors-17-02018-f005}

![The normalized increment of magnetization ΔM~AFP~/M~AFP,0~ as a function of Ф~AFP~ with data analyzed at μ~0~H = 0.065 T. On the standard curve, AFP levels for healthy persons and HCC patients are shown.](sensors-17-02018-g006){#sensors-17-02018-f006}
